Scientists are hailing a potential new dawn in the treatment of bowel cancer after finding a combination of drugs had shrunk tumours in the majority of patients. Botensilimab and balstilimab could “offer new hope” for those diagnosed with a form of the deadly disease that has previously not responded to immunotherapy, researchers from Anglia Ruskin University said. Both drugs work by triggering the body’s immune system to attack cancer cells. Describing the treatment as “potentially game changing”, the team said it hopes authorities in the UK will be “able to move quickly” in approving its use…